HTATIP2 and hepatocellular carcinoma: Metformin (the first-line medication for the treatment of type II diabetes) has been tested in addition to sorafenib, showing inhibited expression of HIF-2α but upregulation of TIP30 at the protein levels, recovering the sensitivity of hypoxic HCC cells to sorafenib therapy in vitro.